Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Helius THC10:CBD10 for insomnia in chronic back pain
ACTRN12623000870651Phase 3Recruiting
- Sponsor
- The University of Auckland
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Helius THC10:CBD10 in Insomnia and chronic back pain (2 arms), sponsored by The University of Auckland. Primary endpoint: Change in Insomnia Severity Index score. Started Oct 2025; status: recruiting.
02
Drugs
Helius THC10:CBD10
03
Conditions
Insomniachronic back pain
Beyond the preview
Go deeper on ACTRN12623000870651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000870651.